Boosted protease inhibitor (PI/r) monotherapy is effective in clinical practice

被引：0
|
作者：
Simpkin, E. [1 ]
Richardson, C. [1 ]
Fisher, M. [1 ]
机构：
[1] BSUH NHS Trust, Brighton, E Sussex, England
来源：
HIV MEDICINE | 2010年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [21] Delays in protease inhibitor use in clinical practice
    Fairfield, KM
    Libman, H
    Davis, RB
    Eisenberg, DM
    Phillips, RS
    JOURNAL OF GENERAL INTERNAL MEDICINE, 1999, 14 (07) : 395 - 401
  • [22] Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting
    Di Benedetto, Nicolas
    Montero-Alonso, Marta
    Blanes, Marino
    Lacruz, Jose
    Cuellar, Sandra
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2015, 28 (05) : 235 - 241
  • [23] Boosted Protease Inhibitor Monotherapy. What Have We Learnt after Seven Years of Research?
    Pulido, Federico
    Matarranz, Mariano
    Rodriguez-Rivera, Violeta
    Fiorante, Silvana
    Hemando, Asuncion
    AIDS REVIEWS, 2010, 12 (03) : 127 - 134
  • [24] Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
    Pasquau, Juan
    Lopez-Cortes, Luis
    Isabel Mayorga, Maria
    Viciana, Pompeyo
    del Mar Arenas, Maria
    Jose Rios, Maria
    Hernandez-Quero, Jose
    Castano, Manuel
    Dolores Merino, Maria
    Marquez, Manuel
    Vergara, Antonio
    Terron, Alberto
    Tellez, Francisco
    Hidalgo-Tenorio, Carmen
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 196 - 197
  • [25] Tipranavir: A ritonavir-boosted protease inhibitor
    Hicks, C
    DRUGS, 2005, 65 (12) : 1678 - 1678
  • [26] TipranavirA Ritonavir-Boosted Protease Inhibitor
    Katherine F. Croom
    Susan J. Keam
    Drugs, 2005, 65 : 1669 - 1677
  • [27] Virological efficacy of PI monotherapy for HIV-1 in clinical practice
    El Bouzidi, Kate
    Collier, Dami
    Nastouli, Eleni
    Copas, Andrew J.
    Miller, Robert F.
    Gupta, Ravindra K.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (11) : 3228 - 3234
  • [28] Is Ritonavir-boosted Protease Inhibitors (PIs/r) monotherapy noninferior to classic combined antiretroviral therapy (cART)?
    Mikula, Tomasz
    Dabrowska, Magdalena
    Wiercinska-Drapalo, Alicja
    HIV & AIDS REVIEW, 2010, 9 (03): : 61 - 64
  • [29] Selection of protease inhibitor (PI) resistance mutations during virological failure of lopinavir/ritonavir (LPV/r) monotherapy in an induction-maintenance study
    Hackett, J. R., Jr.
    Holzmayer, V.
    Marlowe, N.
    DeHaan, M. P.
    Robinson, K. Y.
    Wikstrom, K. J.
    Niemi, K. R.
    King, M. S.
    da Silva, B. A.
    Hanna, G. J.
    ANTIVIRAL THERAPY, 2006, 11 (05) : S85 - S85
  • [30] Protease inhibitor monotherapy and the CNS: peace of mind?
    Perez-Valero, Ignacio
    Bayon, Carmen
    Cambron, Irene
    Gonzalez, Alicia
    Arribas, Jose R.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (09) : 1954 - 1962
12345